Hospital Mater Dei S.A. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Hospital Mater Dei S.A. (BVMF:MATD3) defied analyst predictions to release its quarterly results, which were ahead of market expectations. Hospital Mater Dei beat earnings, with revenues hitting R$583m, ahead of expectations, and statutory earnings per share outperforming analyst reckonings by a solid 14%. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

Check out our latest analysis for Hospital Mater Dei

Taking into account the latest results, the current consensus from Hospital Mater Dei's five analysts is for revenues of R$2.43b in 2024. This would reflect a solid 8.1% increase on its revenue over the past 12 months. Before this earnings report, the analysts had been forecasting revenues of R$2.48b and earnings per share (EPS) of R$0.48 in 2024. So we can see that while the consensus made no real change to its revenue estimates, it also no longer provides an earnings per share estimate. This suggests that revenues are what the market is focusing on after the latest results.

We'd also point out that thatthe analysts have made no major changes to their price target of R$9.66. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Hospital Mater Dei, with the most bullish analyst valuing it at R$13.00 and the most bearish at R$8.00 per share. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.

Of course, another way to look at these forecasts is to place them into context against the industry itself. We would highlight that Hospital Mater Dei's revenue growth is expected to slow, with the forecast 11% annualised growth rate until the end of 2024 being well below the historical 35% p.a. growth over the last three years. Compare this to the 12 other companies in this industry with analyst coverage, which are forecast to grow their revenue at 9.2% per year. So it's pretty clear that, while Hospital Mater Dei's revenue growth is expected to slow, it's expected to grow roughly in line with the industry.

The Bottom Line

The clear take away from these updates is that the analysts made no change to their revenue estimates for next year, with the business apparently performing in line with their models. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

We have estimates for Hospital Mater Dei from its five analysts out to 2026, and you can see them free on our platform here.

You should always think about risks though. Case in point, we've spotted 1 warning sign for Hospital Mater Dei you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.